[go: up one dir, main page]

WO2005071401A2 - Dosage multiplex homogene pour des cibles d'acides nucleiques - Google Patents

Dosage multiplex homogene pour des cibles d'acides nucleiques Download PDF

Info

Publication number
WO2005071401A2
WO2005071401A2 PCT/US2005/001378 US2005001378W WO2005071401A2 WO 2005071401 A2 WO2005071401 A2 WO 2005071401A2 US 2005001378 W US2005001378 W US 2005001378W WO 2005071401 A2 WO2005071401 A2 WO 2005071401A2
Authority
WO
WIPO (PCT)
Prior art keywords
capture probe
reporter
nucleic acid
detectable
probe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/001378
Other languages
English (en)
Other versions
WO2005071401A3 (fr
Inventor
Venkatakrishna Shyamala
Steve H. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2005071401A2 publication Critical patent/WO2005071401A2/fr
Publication of WO2005071401A3 publication Critical patent/WO2005071401A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/588—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with semiconductor nanocrystal label, e.g. quantum dots
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles

Definitions

  • the present invention relates to methods for the detection of specific nucleic acid target sequences in biological samples.
  • nucleic acids found in clinical and environmental specimens are important in medicine and scientific study.
  • a wide variety of assays for such nucleic acid detection and/or analysis are known in the art and vary considerably with regard to specificity, sensitivity, ease and speed of use, and capacity for the number of nucleic acids and/or specimens involved in the assay.
  • Multiplex analysis is the ability to perform multiple discrete assays in a single reaction vessel with the same sample at the same time. Developments in bioanalytical sciences and bioengineering have lead to multiplexed assays for detection and analysis of nucleic acids. See, for example, U.S. Pat. No.
  • nucleic acid assays have used multicolor optical coding technology in combination with nucleic acid hybridization technology to specifically identify a particular nucleic acid species within a complex populations of nucleic acids. See, for example, U.S. Pat. Application Publication No. US 2002/0009728; Spiro et al. (2002) Appl. Environ. Microbiol. 68:1010-1013; Han et al. (2001) Nat. Biotechnol.
  • the present invention provides a homogeneous, multiplexed assay for determination of the presence of nucleic acid target sequences in a sample.
  • the method of the present invention is particularly suitable for the simultaneous detection of multiple nucleic acid target sequences in a single sample with a minimum of physical manipulations.
  • the nucleic acid target sequences can be the products of an amplification reaction ("amplicons").
  • the assay utilizes specific capture probe conjugates having distinguishable spectral signatures and reporter probes.
  • the reporter probes are selectively labeled with a detectable reporter moiety having a signal that is distinguishable from that of the capture probe conjugates.
  • the capture probe conjugates and the reporter probe are capable of specific hybridization to the nucleic acid target sequence.
  • a method comprising contacting a sample suspected of containing the nucleic acid target sequence with a capture probe conjugate, a reporter probe and a detectable reporter moiety under conditions that allow hybridization of the capture probe conjugate and the reporter probe to the nucleic acid target sequence, and association of the detectable reporter moiety with the reporter probe.
  • multiple capture probe conjugates and multiple reporter probes are used allowing the detection of multiple nucleic acid target sequences simultaneously.
  • the capture probe conjugate, the reporter probe, the detectable reporter moiety, and the sample suspected of containing the nucleic acid target sequence are combined.
  • a plurality of targets can be detected simultaneously by combining a capture probe conjugate and reporter probe for each desired target polynucleotide.
  • a complex is formed including the nucleic acid target sequence, capture probe conjugate, reporter probe and detectable reporter moiety.
  • no complex is formed.
  • Each complex is analyzed individually for the presence of the spectral signature of the capture probe in association with the signal from the detectable reporter moiety.
  • Typical assays involve determining the presence of the amplification product in the sample or its relative amount, or the assays may be quantitative or sen ⁇ i-quantitative. Results from such assays can be used to determine the presence or amount of the target polynucleotide originally present in the sample.
  • Kits comprising reagents useful for performing the methods of the invention are also provided.
  • Fig. 1 depicts a single complex formed from capture probe conjugate, nucleic acid target sequence, reporter probe and detectable reporter moiety.
  • Fig. 2 shows representative results of a multiplex assay for HAV, HB V, HCV, HlVa, HIVb and Parvovirus B19 nucleic acid target sequences.
  • Fig. 3 A-3F depicts sequences of capture probe and reporter probe for various viral targets and control.
  • Fig. 4A-4B shows the results of multiplex analyses.
  • Beadset 10 HAV capture probe
  • Beadset 20 HBV capture probe
  • Beadset 30 HCV capture probe
  • Beadset 40 HlVa capture probe
  • Beadset 50 HIVb capture probe
  • Beadset 60 Parvo B19 capture probe
  • Beadset 200 control.
  • a nucleic acid target sequence includes a plurality of target polynucleotides
  • reference to “a substrate” includes a plurality of such substrates
  • reference to “a capture probe” includes a plurality of capture probes, and the like.
  • any range can independently be included in or excluded from the range, and each range where either, neither or both limits are included is also encompassed within the invention.
  • a value being discussed has inherent limits, for example where a component can be present at a concentration of from 0 to 100%, or where the pH of an aqueous solution can range from 1 to 14, those inherent limits are specifically disclosed.
  • a value is explicitly recited, it is to be understood that values which are about the same quantity or amount as the recited value are also within the scope of the invention.
  • a combination is disclosed, each subcombination of the elements of that combination is also specifically disclosed and is within the scope of the invention. Conversely, where different elements or groups of elements are disclosed, combinations thereof are also disclosed.
  • SCTSTC semiconductor nanocrystal
  • Quantum dot refers to an inorganic crystallite of about 1 ⁇ m or more and about 1000 nm or less in diameter or any integer or fraction of an integer therebetween, preferably at least about 2 nm and about 50 nm or less in diameter or any integer or fraction of an integer therebetween, more preferably at least about 2 nm and about 20 nm or less in diameter (for example about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nm). SCNCs are characterized by their uniform nanometer size.
  • An SCNC is capable of emitting electromagnetic radiation upon excitation (i.e., the SCNC is luminescent) and includes a "core" of one or more first semiconductor materials, which may be surrounded by a “shell” of a second semiconductor material.
  • An SCNC core surrounded by a semiconductor shell is referred to as a "core/shell” SCNC.
  • the surrounding "shell" material will preferably have a bandgap energy that is larger than the bandgap energy of the core material and may be chosen to have an atomic spacing close to that of the "core" substrate.
  • the core and/or the shell can be a semiconductor material including, but not limited to, those of the group II- VI (ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, HgS, HgSe, HgTe, MgS, MgSe, MgTe, CaS, CaSe, CaTe, SrS, SrSe, SrTe, BaS, BaSe, BaTe, and the like) and III-V (GaN, GaP, GaAs, GaSb, InN, InP, InAs, InSb, and the like) and IV (Ge, Si, and the like) materials, Pb, PbS, PbSe, and an alloy or a mixture thereof.
  • group II- VI ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe, HgS, HgSe, HgTe, MgS, MgSe,
  • An SCNC is optionally surrounded by a "coat" of an organic capping agent.
  • the organic capping agent may be any number of materials, but has an affinity for the SCNC surface.
  • the capping agent can be an isolated organic molecule, a polymer (or a monomer for a polymerization reaction), an inorganic complex, or an extended crystalline structure.
  • the coat can be used to convey solubility, e.g., the ability to disperse a coated SCNC homogeneously into a chosen solvent, functionality, binding properties, or the like.
  • the coat can be used to tailor the optical properties of the SCNC.
  • SCNC semiconductor nanocrystal
  • quantum dot include a coated SCNC core, as well as a core/shell SCNC.
  • SCNC are described in e.g., U.S. Pat. Nos. 5,990,479, 6,207,229, 6,319,426, 6,322,901, 6,251,303.
  • polynucleotide oligonucleotide
  • nucleic acid nucleic acid molecule
  • nucleic acid molecule polymeric form of nucleotides of any length, and may comprise ribonucleotides, deoxyribonucleotides, analogs thereof, or mixtures thereof. This term refers only to the primary structure of the molecule. Thus, the term includes triple-, double- and single-stranded deoxyribonucleic acid (“DNA”), as well as triple-, double- and single-stranded ribonucleic acid (“RNA").
  • DNA triple-, double- and single-stranded deoxyribonucleic acid
  • RNA triple-, double- and single-stranded ribonucleic acid
  • polynucleotide oligonucleotide
  • nucleic acid containing D-ribose
  • polyribonucleotides including tRNA, rRNA, hRNA, and mRNA, whether spliced or unspliced, any other type of polynucleotide which is an N- or C-glycoside of a purine or pyrimidine base, and other polymers containing normucleotidic backbones, for example, polyamide (e.g., peptide nucleic acids (“PNAs”)) and polymorpholino (commercially available from the Anti-Virals, Inc., Corvallis, OR., as Neugene) polyamide
  • PNAs peptide nucleic acids
  • these terms include, for example, 3'-deoxy-2',5'-DNA, oligodeoxyribonucleotide N3' P5' phosphoramidates, 2'-O-alkyl-substituted RNA, double- and single-stranded DNA, as well as double- and single-stranded RNA, and hybrids thereof including for example hybrids between DNA and RNA or between PNAs and DNA or RNA, and also include known types of modifications, for example, labels, alkylation, "caps," substitution of one or more of the nucleotides with an analog, intemucleotide modifications such as, for example, those with uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), with negatively charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), and with positively charged linkages (e.g., aminoalkylphosphoramidates,
  • nucleases nucleases
  • toxins antibodies
  • signal peptides poly-L-lysine, etc.
  • intercalators e.g., acridine, psoralen, etc.
  • chelates of, e.g., metals, radioactive metals, boron, oxidative metals, etc.
  • alkylators those with modified linkages (e.g., alpha anomeric nucleic acids, etc.), as well as unmodified fonns of the polynucleotide or oligonucleotide.
  • nucleoside and nucleotide will include those moieties which contain not only the known purine and pyrimidine bases, but also other heterocyclic bases which have been modified. Such modifications include methylated purines or pyrimidines, acylated purines or pyrimidines, or other heterocycles. Modified nucleosides or nucleotides can also include modifications on the sugar moiety, e.g., wherein one or more of the hydroxyl groups are replaced with halogen, aliphatic groups, or are functionalized as ethers, amines, or the like.
  • nucleotidic unit is intended to encompass nucleosides and nucleotides.
  • modifications to nucleotidic units include rearranging, appending, substituting for or otherwise altering functional groups on the purine or pyrimidine base which form hydrogen bonds to a respective complementary pyrimidine or purine.
  • the resultant modified nucleotidic unit optionally may form a base pair with other such modified nucleotidic units but not with A, T, C, G or U.
  • Abasic sites may be incorporated which do not prevent the function of the polynucleotide.
  • Some or all of the residues in the polynucleotide can optionally be modified in one or more ways.
  • Standard A-T and G-C base pairs form under conditions which allow the formation of hydrogen bonds between the N3-H and C4-oxy of thymidine and the Nl and C6-NH 2 , respectively, of adenosine and between the C2-oxy, N3 and C4-NH 2 , of cytidine and the C2- NH 2 , N'-H and C6-oxy, respectively, of guanosine.
  • guanosine (2-amino-6- oxy-9-O-D-ribofuran- osyl-purine) may be modified to form isoguanosine (2-oxy-6-amino-9- ⁇ D-ribofuranosyl-purine).
  • nucleic acid probe and “probe” are used interchangeably and refer to a structure comprising a polynucleotide, as defined above, that contains a nucleic acid sequence that can bind to a corresponding target.
  • the polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs.
  • “Complementary” or “substantially complementary” refers to the ability to hybridize or base pair between nucleotides or nucleic acids, such as, for instance, between the two strands of a double stranded DNA molecule or between a polynucleotide primer and a primer binding site on a single stranded nucleic acid to be sequenced or amplified.
  • Complementary nucleotides are, generally, A and T (or A and U), or C and G.
  • Two single- stranded RNA or DNA molecules are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared and with appropriate nucleotide insertions or deletions, pair with at least about 80% of the nucleotides of the other strand, usually at least about 90% to 95%, and more preferably from about 98 to 100%.
  • substantial complementarity exists when an RNA or DNA strand will hybridize under selective hybridization conditions to its complement.
  • selective hybridization will occur when there is at least about 65% complementary over a stretch of at least 14 to 25 nucleotides, preferably at least about 75%, more preferably at least about 90% complementary. See, M. Kanehisa Nucleic Acids Res.
  • Preferential binding refers to the increased propensity of one polynucleotide or capture probe or reporter probe to bind to a complementary target polynucleotide in a sample as compared to noncomplementary polynucleotides in the sample or as compared to the propensity of the one polynucleotide to form an internal secondary structure such as a hairpin or stem-loop structure under at least one set of hybridization conditions.
  • Stringent hybridization conditions will typically include salt concentrations of less than about 1M, more usually less than about 500 mM and preferably less than about 200 mM.
  • Hybridization temperatures can be as low as 5°C, but are typically greater than 22°C, more typically greater than about 30°C, and preferably in excess of about 37°C. Longer fragments may require higher hybridization temperatures for specific hybridization. Other factors may affect the stringency of hybridization, including base composition and length of the complementary strands, presence of organic solvents and extent of base mismatching, and the combination of parameters used is more important than the absolute measure of any one alone.
  • hybridization conditions which may be controlled include buffer type and concentration, solution pH, presence and concentration of blocking reagents to decrease background binding such as repeat sequences or blocking protein solutions, detergent type(s) and concentrations, molecules such as polymers which increase the relative concentration of the polynucleotides, metal ion(s) and their concentration(s), chelator(s) and their concentrations, and other conditions known in the art.
  • buffer type and concentration such as a buffer pH, presence and concentration of blocking reagents to decrease background binding
  • detergent type(s) and concentrations molecules such as polymers which increase the relative concentration of the polynucleotides, metal ion(s) and their concentration(s), chelator(s) and their concentrations, and other conditions known in the art.
  • a labeled polynucleotide amplification product cycles on and off a substrate linked to a capture probe during a real-time assay which is monitored during PCR amplification such as a molecular beacon assay.
  • Such less stringent hybridization conditions can also comprise solution conditions effective for other aspects of the method, for example reverse transcription or PCR.
  • substrate and “support” are used interchangeably and refer to a material having a rigid or semi-rigid surface.
  • binding pair refers to first and second molecules that bind specifically to each other with greater affinity than to other components in the sample. The binding between the members of the binding pair is typically noncovalent.
  • Exemplary binding pairs include immunological binding pairs (e.g., any haptenic or antigenic compound in combination with a corresponding antibody or binding portion or fragment thereof, for example digoxigenin and anti-digoxigenin, fluorescein and anti-fluorescein, dinitroprienol and anti-dinitrophenol, bromodeoxyuridine and anti-bromodeoxyuridine, mouse immuno globulin and goat anti-mouse immunoglobulin) and nonimmunological binding pairs (e.g., biotin- avidin, biotin-streptavidin, hormone [e.g., thyroxine and cortisol] -hormone binding protein, receptor-receptor agonist or antagonist (e.g., acetylcholine receptor-acetylcholine or an analog thereof) IgG-protein A, lectin-carbohydrate, enzyme-enzyme cofactor, enzyme-enzyme- inhibitor, and complementary polynucleotide pairs capable of forming nucleic acid du
  • antibody includes antibodies obtained from both polyclonal and monoclonal preparations, as well as: hybrid (chimeric) antibody molecules (see, for example, Winter et al. (1991) Nature 349:293-299; and U.S. Pat. No. 4,816,567); F(ab')2 and F(ab) fragments; Fv molecules (noncovalent heterodimers, see, for example, Inbar et al. (1972) Proc. Natl. Acad. Sci. USA 69:2659-2662; and Ehrlich et al. (1980) Biochem.
  • a "homogeneous assay” is one that is performed without transfer, separation or washing steps.
  • a homogeneous high-throughput screening (“HTS”) assay involves the initial addition of reagents to a vessel, e.g., a test tube or sample well, followed by the detection of the results from that vessel.
  • a homogeneous HTS assay can be performed anywhere in the vessel, for example in the solution, on the surface of the vessel or on beads or surfaces placed in the vessel.
  • Multiplexing or “multiplex assay” herein refers to an assay or other analytical method in which the presence of multiple nucleic acid target sequences can be assayed simultaneously by using more than one capture probe conjugate, each of which has at least one different detection characteristic, e.g., fluorescence characteristic (for example excitation wavelength, emission wavelength, emission intensity, FWHM (full width at half maximum peak height), or fluorescence lifetime).
  • fluorescence characteristic for example excitation wavelength, emission wavelength, emission intensity, FWHM (full width at half maximum peak height), or fluorescence lifetime.
  • the assays of the present invention may be implemented in a multiplex format.
  • Multiplex methods are provided employing 2, 3, 4, 5, 10, 15, 20, 25, 50, 100, 200, 5O0, 1000 or more different capture probes which can be used simultaneously to assay for amplification products from corresponding different target polynucleotides.
  • multiplex methods can also be used to assay for nucleic acid target sequences which have not undergone an amplification procedure. Methods amenable to multiplexing, such as those taught herein, allow acquisition of greater amounts of information from smaller specimens. The need for smaller specimens increases the ability of an investigator to obtain samples from a larger number of individuals in a population to validate a new assay or simply to acquire data, as less invasive techniques are needed.
  • the different substrates can be encoded so that they can be distinguished. Any encoding scheme can be used; conveniently, the encoding scheme can employ one or more different fluorophores, which can be fluorescent semiconductor nanocrystals. High density spectral coding schemes can be used. [0040] One or more different populations of spectrally encoded capture probe conjugates can be created, each population comprising one or more different capture probes attached to a substrate comprising a known or determinable spectral code comprising one or more semiconductor nanocrystals or fluorescent nanoparticle.
  • Different populations of the conjugates, and thus different assays, can be blended together, and the assay can be performed in the presence of the blended populations.
  • the individual conjugates are scanned for their spectral properties, which allows the spectral code to be decoded and thus identifies the substrate, and therefore the capture probe(s) to which it is attached. Because of the large number of different semiconductor nanocrystals and fluorescent nanoparticles and combinations thereof which can be distinguished, large numbers of different capture probes and amplification products can be simultaneously interrogated.
  • the invention provides a method for detection of a nucleic acid target sequence in a sample comprising: (a) contacting said sample with a capture probe conjugate, a reporter probe and a detectable reporter moiety, under conditions allowing the formation of a complex including said a nucleic acid target sequence, if present, said capture probe conjugate, said reporter probe and said detectable reporter moiety, wherein said capture probe conjugate and said reporter probe each comprise an oligonucleotide that is capable of specifically hybridizing to said nucleic acid target sequence and wherein said capture probe conjugate and said reporter probe do not hybridize to the same or overlapping regions of said nucleic acid target sequence, wherein said capture probe conjugate comprises a substrate having a distinguishable spectral signature that uniquely identifies the capture probe conjugate, wherein said reporter probe comprises one member of a binding pair and said detectable reporter moiety comprises the other member of said binding pair, and wherein said detectable reporter moiety comprises a detectable label; and (b) detecting the signal
  • a method for detection of the presence of a plurality of nucleic acid target sequences in a sample comprising (a) contacting said sample, in a single vessel, with a plurality of capture probe conjugates, a plurality of reporter probes and a detectable reporter moiety, wherein each member of said plurality of capture probe conjugates is specific for one member of said plurality of said target sequences (the specific capture probe conjugate) and each member of said plurality of reporter probes is specific for one member of said plurality of target sequences (the specific reporter probe), under conditions allowing the formation of a specific complex including said a nucleic acid target sequence, if present, said specific capture probe conjugate, said specific reporter probe and said detectable reporter moiety, wherein
  • the method provides that the sample is the product of an amplification reaction, wherein the amplification reaction utilizes one or more oligonucleotide primers in a process of enzymatic extension of said primer(s) to produce multiple copies of a nucleic acid target sequence.
  • the capture probe conjugate and the reporter probe are designed so as not to hybridize to the oligonucleotide primers used in the amplification reaction.
  • the capture probe conjugate comprises a capture probe and a detectable substrate. A detectable substrate that produces a different distinguishable spectral signal is used for each different capture probe.
  • the capture probe conjugates are provided by binding the capture probe, covalently or non-covalently, to the detectable substrate.
  • detectable substrates are available (for example, from Luminex Corp, Austin, TX or Quantum Dot Corp., Hayward, CA).
  • detectable substrates include fluorescent semiconductor nanocrystals, also called quantum dots (for example, as described in U.S. Pat. Nos. 5,990,479, 6,139,426, 6,322,901, 6,207,229, 6,251,303, 6,576,291), quantum beads which are fluorescent microspheres that comprise variable mixtures of quantum dots to provide a large variety of distinguishable emission signals (for example, as described in U.S. Pat. Nos. 6,207,392 and 6,500,622) and fluorescent polymeric microspheres (for example, as described in U.S. Pat. Nos.
  • the capture probe is a single stranded oligonucleotide that is capable of hybridizing specifically to a particular nucleic acid target sequence.
  • the sequence of the capture probe will be sufficiently complementary to the sequence of the nucleic acid target sequence to permit specific hybridization under the conditions of the assay described herein.
  • the length of the capture probe can vary and is often from about 5-100 nucleotides in length. Typically, the capture probe is between about 8 and about 60 nucleotides in length. Preferably, the capture probe is between about 20 and about 30 nucleotides in length.
  • oligonucleotides are well known in the art and the capture probe can be synthesized by any convenient method.
  • the capture probe can be attached to the detectable substrate by any appropriate method. Numerous methods for coupling oligonucleotides to such substrates have been described, for example, in U.S. Pat. Nos. 5,990,479, 6,207,392, 6,423,551, 6,251,303, 6,319,426, 6,426,513, 6,444,143, 4,181,636, 6,649,414, Xu et al. (2003) Nucleic Acids Res. Vol. 31 e 43, Chan et al. (2002) Curr. Opin. Biotech. 13:40, Smith et al. (1998) Clin. Chem.
  • the capture probe can be linked directly or indirectly to the substrate.
  • the capture probe can be linked to the substrate at any point in the oligonucleotide which allows its use under assay conditions.
  • the capture probe is a polynucleotide, it can be synthesized directly on the substrate, or can be synthesized separately from the substrate and then coupled to it. Direct synthesis on the substrate may be accomplished by incorporating a monomer that is coupled to a subunit of the capture probe into a polymer that makes up or is deposited on or coupled to the substrate, and then synthesizing the remainder of the capture probe to incorporate that subunit.
  • the substrate or its coating may include or be derivatized to include a functional group which can be coupled to a subunit of the capture probe for synthesis, or may be coupled directly to the complete capture probe. Suitable coupling techniques are known in the art.
  • the length of the capture probe polynucleotide is not critical, but typically is from 5-100 nucleotides in length and is chosen to provide suitably specific hybridization to the target polynucleotide.
  • the substrate can be in the fonn of a microsphere.
  • Polymeric microspheres or beads can be prepared from a variety of different polymers, including but not limited to polystyrene, cross-linked polystyrene, polyacrylic, polylactic acid, polyglycolic acid, poly(lactide coglycolide), polyanhydrides, poly(methyl methacrylate), poly(ethylene-co-vinyl acetate), polysiloxanes, polymeric silica, latexes, dextran polymers and epoxies.
  • the materials have a variety of different properties with regard to swelling and porosity, which are well understood in the art.
  • the beads are in the size range of approximately 10 nm to 1 mm, and can be manipulated using normal solution techniques when suspended in a solution.
  • the reporter probe is a single stranded oligonucleotide that is capable of hybridizing specifically to a particular nucleic acid target sequence.
  • the sequence of the reporter probe will be sufficiently complementary to the sequence of the nucleic acid target sequence to permit specific hybridization under the conditions of the assay described herein.
  • the length of the reporter probe can vary and is often from about 5-100 nucleotides in length. Typically, the reporter probe is between about 8 and about 60 nucleotides in length. Preferably, the reporter probe is between about 20 and about 30 nucleotides in length.
  • the reporter probe can be synthesized by any convenient method.
  • the reporter probe will comprise one member of a binding pair.
  • the other member of the binding pair will be associated with the detectable reporter moiety.
  • a "binding pair” includes any two molecules, macromolecules or other moieties that bind each other with high affinity and specificity. Many such binding pairs are well known, for example antigen and antibody, receptor and ligand, biotin and avidin streptavidin.
  • the reporter probe will comprise a biotin moiety and the detectable reporter moiety will comprise an avidin or streptavidin attached to a detectable label, preferably a fluorescent label.
  • the detectable reporter moiety is preferably a streptavidin-phycoerythrin conjugate.
  • detectable reporter moieties are well known and commercially available (e.g., from Molecular Probes, Inc.).
  • the nucleic acid target sequence is an amplified sequence ("amplicon"), although in some instances, unamplified sequences may be suitable, e.g., where the nucleic acid target sequences are present in high concentration without amplification.
  • Amplification of the nucleic acid target sequence can be accomplished using any of the well known nucleic acid amplification methods, including polymerase chain reaction (PCR), RT-PCR, transcription mediated amplification (TMA), Nucleic Acid Sequence Based Amplification (NASBA).
  • PCR method for amplifying target nucleic acid sequences in a sample is well known in the art and has been described in, e.g., Innis et al. (eds.) PCR Protocols (Academic Press, NY 1990); Taylor (1991) Polymerase chain reaction: basic principles and automation, in PCR: A Practical Approach, McPherson et al. (eds.) IRL Press, Oxford; Saiki et al. (1986) Nature 324:163; as well as in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,889,818, all incorporated herein by reference in their entireties.
  • RNAs may be amplified by reverse transcribing the mRNA into cDNA, and then performing PCR (RT-PCR), as described above. Alternatively, a single enzyme may be used for both steps as described in U.S. Pat. No. 5,322,770. mRNA may also be reverse transcribed into cDNA, followed by asymmetric gap ligase chain reaction (RT-AGLCR) as described by Marshall et al. (1994) PCR Meth. App. 4:80-84. TMA is described in detail in, e.g., U.S. Pat. No. 5,399,491, the disclosure of which is incorporated herein by reference in its entirety.
  • the reporter probe and the capture probe are complementary to and hybridize with non-overlapping regions of the nucleic acid target sequence. Thus, there is no competition between the capture probe and the reporter probe for hybridization to the nucleic acid target sequence and the capture probe and the reporter probes can both hybridize with the nucleic acid target sequence simultaneously.
  • the reporter probe and the capture probe are designed so as not to hybridize with any amplification primers that may have been used in the amplification reaction to provide the nucleic acid target sequence. This eliminates any competition between the amplicon and the unextended amplification primer for binding to the capture probe or the reporter probe.
  • the method of the present invention is most suitable for use in a homogeneous multiplex analysis of multiple nucleic acid target sequences in a sample.
  • Multiple nucleic acid target sequences can be generated by amplification of a sample by multiple amplification oligonucleotide primers or sets of primers, each primer or set of primers specific for amplifying a particular nucleic acid target sequence.
  • a sample can be analyzed for the presence of multiple viral nucleic acid target sequences by amplification with primers specific for amplification of each of multiple viral target sequences, including, e.g., human immunodeficiency virus (HIV), hepatitis B virus (HBN), hepatitis C virus (HCN), hepatitis A virus (HAN), parvovirus B19, West Nile Virus, hantavirus, severe acute respiratory syndrome- associated coronavirus (SARS), etc.
  • HAV human immunodeficiency virus
  • HBN hepatitis B virus
  • HCN hepatitis C virus
  • HAN hepatitis A virus
  • parvovirus B19 e.g., West Nile Virus, hantavirus, severe acute respiratory syndrome- associated coronavirus (SARS), etc.
  • SARS severe acute respiratory syndrome- associated coronavirus
  • An aliquot of the products of the amplification reaction is transferred to a second reaction vessel for contacting capture probe conjugates and reporter probes specific for each amplified nucleic acid target sequence.
  • the capture probe conjugates, the reporter probes and the detectable reporter moiety are transfened to the second reaction vessel, separately or in any combination.
  • the capture probe conjugates, the reporter probes and the detectable reporter moiety can be added to the second reaction vessel in any order.
  • the capture probe conjugates, the reporter probes and the detectable reporter moiety can be added to the second reaction vessel before or after the nucleic acid target sequences.
  • the capture probe conjugates, the reporter probes, the detectable reporter moiety and the sample containing (or suspected to contain) the nucleic acid target sequences are incubated under conditions that allow the formation of a complex.
  • a complex forms as the capture probe conjugate specific for that target sequence hybridizes to the target, the reporter probe specific for that target sequence also hybridizes to the target and the detectable reporter moiety binds to the reporter probe by the association of the binding pair members.
  • the nucleic acid target sequence forms the link between the capture probe conjugate and the reporter probe (with the detectable reporter moiety).
  • Typical conditions for formation of the complex are incubation at 55°C for 30 minutes in IX tetramethylammonium chloride (TMAC) (3M TMAC, 0.1 % Sarkosyl, 50mM TrispH 8, 4mM EDTA) or HEPES buffer (10 mM HEPES( N-[2-Hydroxyethyl]piperazine-N'- [2-ethanesulfonic]) acid), 0.3M NaCl, pH 7.5), but one of ordinary skill in the art could readily determine other suitable incubation conditions.
  • TMAC IX tetramethylammonium chloride
  • HEPES buffer 10 mM HEPES( N-[2-Hydroxyethyl]piperazine-N'- [2-ethanesulfonic]
  • the target is typically subjected to conditions that will denature and separate the strands (e.g., heating at about 98 °C) prior to the annealing reaction.
  • the sample to be analyzed is subjected to analysis by flow cytometry or other instrumentation that uses microfluidics to align the complexes (as well as the uncomplexed components) into a single file so that the complexes can be analyzed individually.
  • Suitable instrumentation includes the Luminex 100 system or the Becton Dickinson FACScan®.
  • an anay of the complexes can be scanned with a laser scanner having an excitation source and emission filters appropriate for the particular capture probe conjugate substrate (e.g., SCNC(s)) and other fluorophore or reporter label used.
  • the anay can be scanned with a wide-field imaging scanner having appropriate excitation and emission filters. Because the capture probe conjugates produce a distinguishable signature signal for each type of capture probe, the coincidence of capture probe signature signal and detectable reporter moiety signal from a single complex is indicative of the presence of nucleic acid target sequence specific for that capture probe.
  • the portion of the sample comprising or suspected of comprising the target polynucleotide can be any source of biological material which comprises polynucleotides that can be obtained from a living organism directly or indirectly, including cells, tissue or fluid, and the deposits left by that organism, including viruses, mycoplasma, and fossils.
  • the sample can also comprise a target polynucleotide prepared through synthetic means, in whole or in part.
  • the sample is obtained as or dispersed in a predominantly aqueous medium.
  • the sample include blood, plasma, urine, semen, milk, sputum, mucus, a buccal swab, a vaginal swab, a rectal swab, an aspirate, a needle biopsy, a section of tissue obtained for example by surgery or autopsy, plasma, serum, spinal fluid, lymph fluid, the external secretions of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, tumors, organs, samples of in vitro cell culture constituents (including but not limited to conditioned medium resulting from the growth of cells in cell culture medium, putatively virally infected cells, recombinant cells, and cell components), and a recombinant source, e.g., a library, comprising polynucleotide sequences.
  • a recombinant source e.g., a library, comprising polynucleotide sequence
  • the sample can be a positive control sample which is known to contain the target polynucleotide or a surrogate therefor.
  • a negative control sample can also be used which, although not expected to contain the target polynucleotide, is suspected of containing it, and is tested in order to confirm the lack of contamination by the target polynucleotide of the reagents used in a given assay, as well as to determine whether a given set of assay conditions produces false positives (a positive signal even in the absence of target polynucleotide in the sample).
  • the sample can be diluted, dissolved, suspended, extracted or otherwise treated to solubilize and/or purify any target polynucleotide present or to render it accessible to reagents which are used in an amplification scheme or to detection reagents.
  • the cells can be lysed or permeabilized to release the polynucleotides within the cells.
  • One step permeabilization buffers can be used to lyse cells which allow further steps to be performed directly after lysis, for example a polymerase chain reaction.
  • methods of the invention can be used to detect the presence of other infectious agents or pathogens in a sample (e.g., bacteria, yeast, parasites). Methods of the invention can also be used to identify and/or study gene variations or mutations. Accordingly, the methods can be used to detect nucleotide sequences associated with increased risk of diseases or disorders, hereditary disorders, drug sensitivity, or drug resistance. Methods of the invention can also be used in forensic applications (e.g., to identify the source of a forensic sample), transplant compatibility testing, paternity testing, in anthropological settings, and so on.
  • the nucleic acid target sequence can be single- stranded, double-stranded, or higher order, and can be linear or circular.
  • Exemplary single- stranded target polynucleotides include mRNA, rRNA, tRNA, hnRNA, ssRNA or ssDNA viral genomes, although these polynucleotides may contain internally complementary sequences and significant secondary structure.
  • Exemplary double-stranded target polynucleotides include genomic DNA, mitochondrial DNA, chloroplast DNA, dsRNA or dsDNA viral genomes, plasmids, phage, and viroids.
  • the target polynucleotide can be prepared synthetically or purified from a biological source.
  • the target polynucleotide may be purified to remove or diminish one or more undesired components of the sample or to concentrate the target polynucleotide prior to amplification. Conversely, where the target polynucleotide is too concentrated for a particular assay, the target polynucleotide may first be diluted. [0063] Following sample collection and optional nucleic acid extraction and purification, the nucleic acid portion of the sample comprising the target polynucleotide can be subjected to one or more preparative reactions. These preparative reactions can include in vitro transcription (IVT), labeling, fragmentation, amplification and other reactions.
  • IVTT in vitro transcription
  • mRNA can first be treated with reverse transcriptase and a primer, which can be the first primer comprising the target noncomplementary region, to create cDNA prior to detection and/or further amplification; this can be done in vitro with purified mRNA or in situ, e.g., in cells or tissues affixed to a slide. Nucleic acid amplification increases the copy number of sequences of interest and can be used to incorporate a label into an amplification product produced from the target polynucleotide using a labeled primer or labeled nucleotide.
  • amplification methods are suitable for use, including the polymerase chain reaction method (PCR), transcription mediated amplification (TMA), the ligase chain reaction (LCR), self sustained sequence replication (3SR), nucleic acid sequence-based amplification (NASBA), the use of Q Beta replicase, reverse transcription, nick translation, and the like, particularly where a labeled amplification product can be produced and utilized in the methods taught herein.
  • PCR polymerase chain reaction method
  • TMA transcription mediated amplification
  • LCR ligase chain reaction
  • NASBA self sustained sequence replication
  • Q Beta replicase Q Beta replicase
  • reverse transcription reverse transcription
  • nick translation and the like
  • the nucleic acid target sequence does not have a label directly incorporated in the sequence.
  • the first cycle of amplification forms a primer extension product complementary to the target polynucleotide. If the target polynucleotide is single-stranded RNA, a polymerase with reverse transcriptase is used in the first amplification to reverse transcribe the RNA to DNA, and additional amplification cycles can be performed to copy the primer extension products.
  • the primers for a PCR must, of course, be designed to hybridize to regions in their conesponding template that will produce an amplifiable segment; thus, each primer must hybridize so that its 3' nucleotide is paired to a nucleotide in its complementary template strand that is located 3' from the 3' nucleotide of the primer used to prime the synthesis of the complementary template strand.
  • the target polynucleotide is typically amplified by contacting one or more strands of the target polynucleotide with a primer and a polymerase having suitable activity to extend the primer and copy the target polynucleotide to produce a full-length complementary polynucleotide or a smaller portion thereof.
  • Any enzyme having a polymerase activity which can copy the target polynucleotide can be used, including DNA polymerases, RNA polymerases, reverse transcriptases, enzymes having more than one type of polymerase activity.
  • the polymerase can be thermolabile or thermostable. Mixtures of enzymes can also be used.
  • Exemplary enzymes include: DNA polymerases such as DNA Polymerase I ("Pol I"), the Klenow fragment of Pol I, T4, T7, SequenaseTM T7, SequenaseTM Version 2.0 T7, Tub, Taq, Tth, Pfx, Pfu, Tsp, Tfl, Tli and Pyrococcus sp GB-D DNA polymerases; RNA polymerases such as E. coli, SP6, T3 and T7 RNA polymerases; and reverse transcriptases such as AMV, M-MuLV, MMLV, RNAse H minus MMLV (SuperscriptTM), SuperscriptTM II, ThermoScriptTM, HIV-1, and RAV2 reverse transcriptases.
  • DNA polymerases such as DNA Polymerase I ("Pol I"), the Klenow fragment of Pol I, T4, T7, SequenaseTM T7, SequenaseTM Version 2.0 T7, Tub, Taq, Tth, Pfx, P
  • Exemplary polymerases with multiple specificities include RAV2 and Tli (exo-) polymerases.
  • Exemplary thermostable polymerases include Tub, Taq, Tth, Pfx, Pfu, Tsp, Tfl, Tli and Pyrococcus sp.
  • GB-D DNA polymerases are commercially available.
  • Suitable reaction conditions are chosen to permit amplification of the target polynucleotide, including pH, buffer, ionic strength, presence and concentration of one or more salts, presence and concentration of reactants and cofactors such as nucleotides and magnesium and/or other metal ions, optional cosolvents, temperature, thermal cycling profile for amplification schemes comprising a polymerase chain reaction, and may depend in part on the polymerase being used as well as the nature of the sample.
  • Cosolvents include formamide (typically at from about 2 to about 10%), glycerol (typically at from about 5 to about 10%), and DMSO (typically at from about 0.9 to about 10%).
  • Techniques maybe used in the amplification scheme in order to minimize the production of false positives or artifacts produced during amplification. These include "touchdown" PCR, hot-start techniques, use of nested primers, or designing PCR primers so that they form stem-loop structures in the event of primer-dimer formation and thus are not amplified.
  • Techniques to accelerate PCR can be used, for example centrifugal PCR, which allows for greater convection within the sample, and comprising infrared heating steps for rapid heating and cooling of the sample.
  • One or more cycles of amplification can be performed.
  • An excess of one primer can be used to produce an excess of one primer extension product during PCR; preferably, the primer extension product produced in excess is the amplification product to be detected.
  • a plurality of different primers may be used to amplify different regions of a particular polynucleotide within the sample.
  • the amplification reaction comprises multiple cycles of amplification with a polymerase, as in PCR, it is desirable to dissociate the primer extension product(s) formed in a given cycle from their template(s).
  • the reaction conditions are therefore altered between cycles to favor such dissociation; typically this is done by elevating the temperature of the reaction mixture, but other reaction conditions can be altered to favor dissociation, for example lowering the salt concentration and/or raising the pH of the solution in which the double- stranded polynucleotide is dissolved.
  • the polynucleotides may be first isolated using any effective technique and transfened to a different solution for dissociation, then reintroduced into an amplification reaction mixture for additional amplification cycles.
  • This assay can be multiplexed, i.e., multiple distinct assays can be run simultaneously, by using different pairs of primers directed at different targets, which can be unrelated targets, or different alleles or subgroups of alleles from, or chromosomal reanangements at, the same locus. This allows the quantitation of the presence of multiple target polynucleotides in a sample (e.g., specific genes in a cDNA library).
  • Amplified target polynucleotides may be subjected to post-amplification treatments. For example, in some cases, it may be desirable to fragment the amplification products prior to hybridization with a polynucleotide anay, in order to provide segments which are more readily accessible and which avoid looping and/or hybridization to multiple capture probes. Fragmentation of the nucleic acids can be carried out by any method producing fragments of a size useful in the assay being performed; suitable physical, chemical and enzymatic methods are known in the art.
  • the detectable reporter moiety comprises one member of a binding pair and a label.
  • the label comprises an agent selected from a chromophore, a lumiphore, a fluorophore, a chromogen, a hapten, an antigen, a radioactive isotope, a magnetic particle, a metal nanoparticle such as a gold or silver nanoparticle, a quantum dot and combinations thereof.
  • a fluorophore can be any substance which absorbs light of one wavelength and emits light of a different wavelength. Typical fluorophores include fluorescent dyes, semiconductor nanocrystals, lanthanide chelates, and a green fluorescent protein.
  • Exemplary fluorescent dyes include fluorescein, 6-FAM, rhodamine, Texas Red®, tetramethylrhodamine, a carboxyrhodamine, carboxyrhodamine 6G, carboxyrhodol, carboxyrhodamine 110, Cascade Blue®, Cascade Yellow®, coumarin, CyTM2, CyTM3, CyTM3.5, CyTM5, CyTM5.5, Cy-Chrome, phycoerythrin, PerCPTM (peridinin chlorophyll-a Protein), PerCPTM-CyTM5.5, JOE (6-carboxy-4',5'-dichloro-2',7'-dimethoxyfluorescein), NED, ROX (5-(and-6)-carboxy-X-rhodamine), HEX, lucifer yellow, Marina Blue®, Oregon Green® 488, Oregon Green® 500, Oregon Green® 514, Alexa Fluor® 350, Alexa Fluor® 430, Alexa Fluor®
  • kits comprising reagents useful for performing the methods of the invention are also provided.
  • a kit comprises a detectable substrate attached to a capture probe and first and second primers for amplifying the target polynucleotide.
  • the substrate can be an encoded bead comprising a first spectral code comprising a first semiconductor nanocrystal and first fluorescence characteristics.
  • the capture probe can bind to the amplification product produced from the target polynucleotide, and a sample may be assayed for the presence of such a target polynucleotide or amplification product produced therefrom using the components of the kit.
  • the kit may also contain a reporter probe that can bind to the amplification product produced from the target polynucleotide and a detectable reporter moiety.
  • the components of the kit are retained by a housing. Instructions for using the kit to perform a method of the invention are provided with the housing, and may be located inside the housing or outside the housing, and may be printed on the interior or exterior of any surface forming the housing which renders the instructions legible.
  • the kit may be in multiplex form, containing pluralities of one or more different capture probe conjugates, reporter probes and/ or pairs of amplification primers.
  • the substrate may comprise a plurality of polynucleotides of different sequence for performing a plurality of individual assays thereon such as a microanay, or a plurality of different beads can be provided for a multiplexed assay wherein each of the different beads comprises a different capture probe for binding to a conesponding different amplification product.
  • Example 1 Homogeneous Multiplex Assay for viral nucleic acid targets using Luminex beads.
  • the Luminex xMap® System (Luminex Corp, Austin, TX) uses polystyrene microspheres of 5.5 microns in diameter to measure multiple analytes simultaneously in a single reaction vessel. One hundred subsets of microspheres are available, which have been created by impregnating a combination of two fluorescent dyes in different proportions to produce a unique spectral signature for each subset. One of two lasers is used to identify the bead subset. A second laser is used to identify a fluorescent label.
  • the fluorescent label of the detectable reporter moiety in turn binds to the reporter probe to signal the extent of the reaction.
  • the capture probe conjugate, reporter probe, fluorescent reporter moiety and the sample containing the target sequences are combined. This mixture is then injected into an instrument that uses microfluidics to align the microspheres in a single file where lasers illuminate the colors inside and on the surface of each microsphere. Since the lasers score only for the dual feature of capture probe bead fluorescence and associated reporter moiety fluorescent marker this has the advantage of being homogeneous assay. Advanced optics capture the color signals and digitally process them into real-time, quantitative data for each reaction.
  • TMA Transcription Mediated Amplification
  • Capture probes complementary to the R ⁇ A amplicons for HCN and HIN are carbodiimide coupled, each to a distinct subset of Luminex carboxylated microspheres according to instructions provided by the supplier (Luminex Corp.).
  • Six different subtypes of microspheres are used to couple to capture probes specific for each of the targets in similar fashion to that described above.
  • HAN capture probe was coupled to Luminex beads L100-C110-04 to produce Bead set 10; HBN capture probe was coupled to Luminex beads L100-C120-04 to produce Bead set 20; HCN capture probe was coupled to Luminex beads L100-C130-04 to produce Bead set 30; HINa capture probe was coupled to Luminex beads L100-C 140-04 to produce Bead set 40; HIVb capture probe was coupled to Luminex beads L100-C 150-04 to produce Bead set 50; ParvoB19 capture probe was coupled to Luminex beads L100-C160-04 to produce Bead set 60; Control capture probe was coupled to Luminex beads L100-C200-04 to produce Bead set 20.
  • Target sequences for multiplexing studies were generated using the Invitrogen (Carlsbad, CA) RNA amplifier kit or synthetic oligonucleotides conesponding to the regions of interest.
  • the nucleic acid targets conesponded to sequences from HCV, HIV, HBV, Parvo virus B19 and HAV.
  • RNA amplicons to the following conesponding regions of HAV(nt 61-300, GenBank Accession M14707), HBV(nt 2881-3121, GenBank Accession X02763), HCVfnt 121-420, GenBank Accession M62321), HIV-la ( nt 4561-4800, GenBank Accession K034551), Parvo B19(nt 3241-3480, GenBank Accession M13178), and internal control (pBR322- nt 600-820, GenBank Accession J01749) derivative sequence were prepared using the RNA amplifier kit. The sequences of the capture probes, reporter probes, and targets used are shown in Figures 3A-3F.
  • Fig. 2 depicts representative graphic results of a multiplex assay using amplified synthetic target.
  • the synthetic target is a synthetic single stranded DNA sequence having sequences from all six viral targets (HAV, HBV, HCV, HlVa , HIVb, ParvoB19).
  • "IC" in Fig. 2 represents results with an internal control.
  • the signal from respective target-capture probe-reporter probe complexes was distinguishable, and simultaneously detectable.
  • Fig. 4 shows the data from one multiplex assay using the synthetic targets.
  • Performance of such assays has demonstrated that one microliter of amplicon generated by a TMA reaction, equivalent to amplicons generated from 1.5 IU of HCV, is sufficient for detection.
  • lx TMAC buffer (3M TMAC, 0.1% Sarkosyl, 50mM TrispH 8, 4mM EDTA) provided optimal conditions for homogenous nucleic acid assay, while HEPES buffer (10 mM HEPES acid), 0.3M NaCl, pH 7.5) was also adequate. 55°C for 30 minutes is an optimal condition for the reaction in TMAC buffer. Slightly shorter incubation times were adequate, but 30 minutes gave the most reproducible results in TMAC buffer. The titration of the streptavidin-phycoerythrin detectable reporter moiety indicated that one to three ug/ul provided the best overall signal and signal to noise ratio. [0085]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Materials Engineering (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention a trait à un procédé pour l'analyse simultanée, dans un format homogène, pour la détection de plusieurs séquences cibles d'acides nucléiques. L'invention utilise des sondes de capture conjuguées à des substrats qui sont diférenciables en fonction d'une signature spectrale unique en combinaison avec des sondes rapporteuses ayant une étiquette séparément détectable. En présence d'une séquence cible, des complexes détectables sont formés qui sont différenciables pour chaque combinaison de cible, sonde de capture et sonde rapporteuse.
PCT/US2005/001378 2004-01-15 2005-01-14 Dosage multiplex homogene pour des cibles d'acides nucleiques Ceased WO2005071401A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53697804P 2004-01-15 2004-01-15
US60/536,978 2004-01-15

Publications (2)

Publication Number Publication Date
WO2005071401A2 true WO2005071401A2 (fr) 2005-08-04
WO2005071401A3 WO2005071401A3 (fr) 2005-12-01

Family

ID=34807070

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/001378 Ceased WO2005071401A2 (fr) 2004-01-15 2005-01-14 Dosage multiplex homogene pour des cibles d'acides nucleiques

Country Status (1)

Country Link
WO (1) WO2005071401A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534588B2 (en) * 2007-05-25 2009-05-19 Asiagen Corporation Methods, kits and polynucleotides for simultaneously diagnosing viruses
JP2009521230A (ja) * 2005-12-23 2009-06-04 ナノストリング テクノロジーズ，インコーポレーテッド ナノレポーターならびにその作製方法および使用方法
WO2011047087A2 (fr) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Détection de protéine par l'intermédiaire de nanorapporteurs
US8063197B2 (en) 2004-07-13 2011-11-22 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
WO2014014309A1 (fr) * 2012-07-20 2014-01-23 부산대학교 산학협력단 Procédé et trousse pour la détection ou la quantification d'une matière cible
CN103616513A (zh) * 2013-12-06 2014-03-05 苏州长光华医生物医学工程有限公司 乙型肝炎病毒e抗原测定试剂盒以及检测方法
CN103630531A (zh) * 2013-12-06 2014-03-12 苏州长光华医生物医学工程有限公司 乙型肝炎表面抗原测定试剂盒以及检测方法
CN104090101A (zh) * 2014-07-21 2014-10-08 威海威高生物科技有限公司 人类免疫缺陷病毒抗体检测试剂盒及其制备方法
US10011811B2 (en) 2013-11-25 2018-07-03 Vericel Corporation Cell seeding device and method
US10563254B2 (en) 2007-01-23 2020-02-18 Cambridge Enterprise Limited Nucleic acid amplification and testing
CN111909932A (zh) * 2020-07-17 2020-11-10 南方医科大学 一种原位检测外泌体多重microRNA的纳米金荧光探针及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8103687A (en) * 1986-10-14 1988-05-06 Beckman Instruments, Inc. Improved nucleic acid hybridization technique and kit therefor
AU2872092A (en) * 1991-10-15 1993-05-21 Multilyte Limited Binding assay employing labelled reagent
US6268147B1 (en) * 1998-11-02 2001-07-31 Kenneth Loren Beattie Nucleic acid analysis using sequence-targeted tandem hybridization
AU2002237662A1 (en) * 2000-11-17 2002-05-27 Surromed, Inc. Analysis of soluble factor biological markers
KR100944674B1 (ko) * 2001-06-28 2010-03-04 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 파르보바이러스 ｂ19의 진단 분석
EP1451352A4 (fr) * 2001-10-09 2006-06-21 Chiron Corp Identification d'oligonucleotides pour la capture, la detection et l'evaluation quantitative de l'adn viral de l'hepatite b

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063197B2 (en) 2004-07-13 2011-11-22 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US8461324B2 (en) 2004-07-13 2013-06-11 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US8563707B2 (en) 2004-07-13 2013-10-22 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US10392656B2 (en) 2004-07-13 2019-08-27 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US9469881B2 (en) 2004-07-13 2016-10-18 Gen-Probe Incorporated Compositions and methods for detection of hepatitis A virus nucleic acid
US9371563B2 (en) 2005-12-23 2016-06-21 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
JP2009521230A (ja) * 2005-12-23 2009-06-04 ナノストリング テクノロジーズ，インコーポレーテッド ナノレポーターならびにその作製方法および使用方法
EP1963531A4 (fr) * 2005-12-23 2009-10-21 Nanostring Technologies Inc Nanorapporteurs et procedes de production et d'utilisation de ceux-ci
US9890419B2 (en) 2005-12-23 2018-02-13 Nanostring Technologies, Inc. Nanoreporters and methods of manufacturing and use thereof
US11447821B2 (en) 2007-01-23 2022-09-20 Cambridge Enterprise Limited Nucleic acid amplification and testing
US10563254B2 (en) 2007-01-23 2020-02-18 Cambridge Enterprise Limited Nucleic acid amplification and testing
US7534588B2 (en) * 2007-05-25 2009-05-19 Asiagen Corporation Methods, kits and polynucleotides for simultaneously diagnosing viruses
US9714937B2 (en) 2009-10-13 2017-07-25 Nanostring Technologies, Inc. Protein detection via nanoreporters
AU2010306862B2 (en) * 2009-10-13 2015-08-27 Bruker Spatial Biology, Inc. Protein detection via nanoreporters
US9995739B2 (en) 2009-10-13 2018-06-12 Nanostring Technologies, Inc. Protein detection via nanoreporters
EP2488876A4 (fr) * 2009-10-13 2013-03-20 Nanostring Technologies Inc Détection de protéine par l'intermédiaire de nanorapporteurs
WO2011047087A2 (fr) 2009-10-13 2011-04-21 Nanostring Technologies, Inc. Détection de protéine par l'intermédiaire de nanorapporteurs
WO2014014309A1 (fr) * 2012-07-20 2014-01-23 부산대학교 산학협력단 Procédé et trousse pour la détection ou la quantification d'une matière cible
US10011811B2 (en) 2013-11-25 2018-07-03 Vericel Corporation Cell seeding device and method
CN103630531A (zh) * 2013-12-06 2014-03-12 苏州长光华医生物医学工程有限公司 乙型肝炎表面抗原测定试剂盒以及检测方法
CN103616513A (zh) * 2013-12-06 2014-03-05 苏州长光华医生物医学工程有限公司 乙型肝炎病毒e抗原测定试剂盒以及检测方法
CN104090101A (zh) * 2014-07-21 2014-10-08 威海威高生物科技有限公司 人类免疫缺陷病毒抗体检测试剂盒及其制备方法
CN111909932A (zh) * 2020-07-17 2020-11-10 南方医科大学 一种原位检测外泌体多重microRNA的纳米金荧光探针及其制备方法与应用

Also Published As

Publication number Publication date
WO2005071401A3 (fr) 2005-12-01

Similar Documents

Publication Publication Date Title
USRE48811E1 (en) Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
US6838243B2 (en) Methods and compositions for polynucleotide analysis using generic capture sequences
US7214489B2 (en) Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores
EP2161343B1 (fr) Procédés et compositions pour la détection et l'analyse des interactions entre des protéines se liant à des polynucléotides utilisant des multichromophores capturant la lumière
US6500622B2 (en) Methods of using semiconductor nanocrystals in bead-based nucleic acid assays
US9310375B2 (en) Luminophore-labeled molecules coupled with particles for microarray-based assays
US20100190657A1 (en) Oligonucleotide-tagged semiconductor nanocrystals for microarray and fluorescence in situ hybridization
US20130190193A1 (en) Compositions for detection and analysis of polynucleotides using light harvesting multichromophores
WO2005071401A2 (fr) Dosage multiplex homogene pour des cibles d'acides nucleiques
US20020115082A1 (en) Methods and compositions for polynucleotide analysis using generic molecular beacons
Ait Hammou et al. Scientific Advances in the Diagnosis of Emerging and Reemerging Viral Human Pathogens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase